Publication

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Journal Paper/Review - Feb 21, 2015

Units
PubMed
Doi

Citation
Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.
Type
Journal Paper/Review (English)
Journal
Swiss Med Wkly 2015; 145
Publication Date
Feb 21, 2015
Issn Electronic
1424-3997
Pages
w14100
Brief description/objective

The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.